Entero Therapeutics (GRDX) Competitors

$3.27 -0.18 (-5.19%)
As of 03:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GRDX vs. EGAN, AIBZ, FUFU, EXFY, and SWMR

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include eGain (EGAN), Bitzero (AIBZ), BitFuFu (FUFU), Expensify (EXFY), and Swarmer (SWMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to eGain?

Entero Therapeutics (NASDAQ:GRDX) and eGain (NASDAQ:EGAN) are both small-cap technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, eGain had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for eGain and 2 mentions for Entero Therapeutics. eGain's average media sentiment score of 0.98 beat Entero Therapeutics' score of 0.34 indicating that eGain is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entero Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
eGain
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 53.9% of eGain shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 41.1% of eGain shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

eGain has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than eGain, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero Therapeutics$40K698.36-$6.39M-$1.90N/A
eGain$89.50M1.55$8.88M$0.2819.68

Entero Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, eGain has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

eGain has a consensus price target of $6.50, indicating a potential upside of 17.97%. Given eGain's stronger consensus rating and higher probable upside, analysts clearly believe eGain is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
eGain
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

eGain has a net margin of 8.50% compared to Entero Therapeutics' net margin of -11,237.77%. eGain's return on equity of 8.76% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero Therapeutics-11,237.77% -65.36% -30.01%
eGain 8.50%8.76%5.31%

Summary

eGain beats Entero Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Bitzero?

Entero Therapeutics (NASDAQ:GRDX) and Bitzero (NASDAQ:AIBZ) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Bitzero has a net margin of 0.00% compared to Entero Therapeutics' net margin of -11,237.77%. Entero Therapeutics' return on equity of -65.36% beat Bitzero's return on equity.

Company Net Margins Return on Equity Return on Assets
Entero Therapeutics-11,237.77% -65.36% -30.01%
Bitzero N/A -167.23%-56.70%

Entero Therapeutics has higher earnings, but lower revenue than Bitzero. Bitzero is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero Therapeutics$40K698.36-$6.39M-$1.90N/A
Bitzero$30.92M3.56-$12.09M-$0.24N/A

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Entero Therapeutics had 2 more articles in the media than Bitzero. MarketBeat recorded 2 mentions for Entero Therapeutics and 0 mentions for Bitzero. Bitzero's average media sentiment score of 1.68 beat Entero Therapeutics' score of 0.34 indicating that Bitzero is being referred to more favorably in the news media.

Company Overall Sentiment
Entero Therapeutics Neutral
Bitzero Very Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bitzero
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Entero Therapeutics beats Bitzero on 8 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to BitFuFu?

BitFuFu (NASDAQ:FUFU) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

BitFuFu has a net margin of -36.00% compared to Entero Therapeutics' net margin of -11,237.77%. BitFuFu's return on equity of -18.05% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BitFuFu-36.00% -18.05% -7.46%
Entero Therapeutics -11,237.77%-65.36%-30.01%

BitFuFu presently has a consensus price target of $4.00, suggesting a potential upside of 298.01%. Given BitFuFu's stronger consensus rating and higher possible upside, analysts plainly believe BitFuFu is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BitFuFu
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Entero Therapeutics has lower revenue, but higher earnings than BitFuFu. Entero Therapeutics is trading at a lower price-to-earnings ratio than BitFuFu, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BitFuFu$475.77M0.35-$31.25M-$0.84N/A
Entero Therapeutics$40K698.36-$6.39M-$1.90N/A

37.3% of BitFuFu shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 35.0% of BitFuFu shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BitFuFu has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

In the previous week, BitFuFu had 13 more articles in the media than Entero Therapeutics. MarketBeat recorded 15 mentions for BitFuFu and 2 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.34 beat BitFuFu's score of 0.26 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BitFuFu
3 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Entero Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BitFuFu beats Entero Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Entero Therapeutics compare to Expensify?

Entero Therapeutics (NASDAQ:GRDX) and Expensify (NASDAQ:EXFY) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Expensify shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 11.7% of Expensify shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Expensify has a net margin of -12.23% compared to Entero Therapeutics' net margin of -11,237.77%. Expensify's return on equity of -12.25% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero Therapeutics-11,237.77% -65.36% -30.01%
Expensify -12.23%-12.25%-8.85%

Expensify has a consensus target price of $3.00, suggesting a potential upside of 100.67%. Given Expensify's stronger consensus rating and higher probable upside, analysts plainly believe Expensify is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Expensify
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Expensify had 19 more articles in the media than Entero Therapeutics. MarketBeat recorded 21 mentions for Expensify and 2 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.34 beat Expensify's score of 0.19 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entero Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Expensify
8 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Entero Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Expensify has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market.

Entero Therapeutics has higher earnings, but lower revenue than Expensify. Expensify is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero Therapeutics$40K698.36-$6.39M-$1.90N/A
Expensify$142.10M0.84-$21.39M-$0.18N/A

Summary

Expensify beats Entero Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Entero Therapeutics compare to Swarmer?

Entero Therapeutics (NASDAQ:GRDX) and Swarmer (NASDAQ:SWMR) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Entero Therapeutics has higher earnings, but lower revenue than Swarmer. Swarmer is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero Therapeutics$40K698.36-$6.39M-$1.90N/A
Swarmer$310K369.71-$8.53M-$0.73N/A

In the previous week, Swarmer had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Swarmer and 2 mentions for Entero Therapeutics. Swarmer's average media sentiment score of 0.56 beat Entero Therapeutics' score of 0.34 indicating that Swarmer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entero Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Swarmer
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Swarmer has a consensus price target of $20.00, suggesting a potential upside of 189.86%. Given Swarmer's stronger consensus rating and higher probable upside, analysts plainly believe Swarmer is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Swarmer
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Swarmer has a net margin of -8,329.07% compared to Entero Therapeutics' net margin of -11,237.77%. Entero Therapeutics' return on equity of -65.36% beat Swarmer's return on equity.

Company Net Margins Return on Equity Return on Assets
Entero Therapeutics-11,237.77% -65.36% -30.01%
Swarmer -8,329.07%-116.45%-86.62%

Summary

Swarmer beats Entero Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRDX vs. The Competition

MetricEntero TherapeuticsSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$28.14M$14.53B$23.72B$10.95B
Dividend YieldN/A3.41%2.98%4.74%
P/E Ratio-1.7346.0541.1728.95
Price / Sales698.366.275.355.39
Price / CashN/A27.1726.3621.66
Price / Book1.825.704.743.52
Net Income-$6.39M$427.42M$794.90M$394.12M
7 Day Performance-12.54%-7.41%-8.76%-8.40%
1 Month Performance-29.35%-10.02%-12.87%-11.53%
1 Year PerformanceN/A-10.47%-0.80%-9.14%

Entero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRDX
Entero Therapeutics
1.025 of 5 stars
$3.27
-5.2%
N/AN/A$28.14M$40KN/A2
EGAN
eGain
2.7384 of 5 stars
$6.20
+1.6%
$6.50
+4.8%
-44.7%$154.41M$89.50M22.14422
AIBZ
Bitzero
0.6896 of 5 stars
$2.66
-5.7%
N/AN/A$152.71M$30.92MN/A8
FUFU
BitFuFu
2.2422 of 5 stars
$0.82
-9.4%
$5.00
+507.1%
-70.2%$151.43M$475.77MN/A29
EXFY
Expensify
3.0388 of 5 stars
$1.84
-1.1%
$3.00
+63.0%
+6.8%$148.90M$142.10MN/A117

Related Companies and Tools


This page (NASDAQ:GRDX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners